Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the company's stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $171.47, for a total value of $514,410.00. Following the transaction, the chief financial officer directly owned 158,096 shares in the company, valued at $27,108,721.12. This represents a 1.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Gilead Sciences Trading Up 1.6%
NASDAQ GILD traded up $2.68 during trading on Tuesday, hitting $170.26. The company's stock had a trading volume of 6,280,613 shares, compared to its average volume of 6,456,805. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. The business's 50 day simple moving average is $155.90 and its 200-day simple moving average is $142.09.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. During the same quarter in the prior year, the company posted $2.47 earnings per share. The company's revenue for the quarter was up 6.8% compared to the same quarter last year. On average, analysts anticipate that Gilead Sciences, Inc. will post -0.97 EPS for the current year.
Gilead Sciences Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences's payout ratio is currently -103.80%.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on the stock. Bank of America raised their price target on shares of Gilead Sciences from $168.00 to $172.00 and gave the stock a "buy" rating in a report on Tuesday, October 20th. Jefferies Financial Group set a $196.00 price objective on shares of Gilead Sciences in a report on Wednesday, November 4th. Wells Fargo & Company upped their target price on Gilead Sciences from $165.00 to $190.00 and gave the company an "overweight" rating in a research report on Friday, October 30th. Leerink Partners lowered Gilead Sciences from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Finally, Barclays lifted their price target on Gilead Sciences from $145.00 to $160.00 and gave the stock an "equal weight" rating in a research report on Monday. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $171.63.
Check Out Our Latest Stock Report on Gilead Sciences
Hedge Funds Weigh In On Gilead Sciences
A number of institutional investors have recently bought and sold shares of GILD. BlackRock Inc. purchased a new stake in shares of Gilead Sciences in the 2nd quarter valued at $15,393,785,000. State Street Corp increased its stake in shares of Gilead Sciences by 2.3% in the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company's stock worth $7,734,099,000 after acquiring an additional 1,357,967 shares during the period. Amundi raised its holdings in shares of Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company's stock worth $1,468,836,000 after purchasing an additional 1,018,976 shares during the last quarter. Legal & General Group Plc purchased a new position in shares of Gilead Sciences during the second quarter worth $1,316,606,000. Finally, Deutsche Bank AG purchased a new position in shares of Gilead Sciences during the second quarter worth $918,387,000. 83.67% of the stock is owned by hedge funds and other institutional investors.
Key Headlines Impacting Gilead Sciences
These are some of the GILD headlines that stood out recently:
- Neutral Sentiment: Gilead executives appeared at the Jefferies and UBS healthcare conferences, but the provided headlines do not identify specific new guidance or announcements that would change the investment outlook. Jefferies conference transcript
- Neutral Sentiment: Gilead completed a new Foster City research center, adding specialized laboratory capacity. This may support research over time, but the completion itself does not indicate a near-term financial impact. Research center completion
- Negative Sentiment: Barclays maintained an equal-weight/hold stance while raising its price target to $160, still below the $170.26 price cited in the stock-performance information. That gap highlights valuation risk after GILD’s strong run. Barclays rating
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.